Almirall, S.A.
ALM.MCAlmonty Industries Inc. is an international mining company primarily engaged in the extraction and development of tungsten resources. The company operates in Spain, Portugal, and South Korea and is publicly traded on the Toronto Stock Exchange (TSX). The current Chief Executive Officer is Lewis Black.
Drugs in Pipeline
27
Phase 3 Programs
13
Upcoming Catalysts
3
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
Lebrikizumab
Atopic Dermatitis
LAS41007
Actinic Keratosis
Tirbanibulin
Keratosis, Actinic
Sarecycline
Acne Vulgaris
KX2-391 Ointment 1%
Actinic Keratosis
Tirbanibulin ointment 1%
Keratosis, Actinic
LAS106521
Actinic Keratosis
Dapsone Gel
Acne Vulgaris
LAS41008
Plaque Psoriasis
5-fluorouracil/salicylic acid
Actinic Keratosis
LAS41005
Actinic Keratosis
Sativex®
Multiple Sclerosis
Dapsone Gel Vehicle
Acne Vulgaris
LAS41004-IMP1
Psoriasis
50 mg of KX2-391 Ointment 1%
Actinic Keratosis
Experimental: LAS 41004 dosage 1
Psoriasis
Experimental Tazarotene Gel
Nail Psoriasis
LAD603
Alopecia Areata
LAS41004
Psoriasis
LAD191
Hidradenitis Suppurativa
LAS189961
Tinea Pedis
50 mg P005672-HCl
Acne Vulgaris
LAS41007 o.d.
Actinic Keratosis
LAS 41004
Psoriasis
LAS 41002
Atopic Eczema
LAS189962
Candidiasis
LAS41003
Eczema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lebrikizumab | Phase 3 | Atopic Dermatitis | - | - |
LAS41007 | Phase 3 | Actinic Keratosis | - | - |
Tirbanibulin | Phase 3 | Keratosis, Actinic | - | - |
Sarecycline | Phase 3 | Acne Vulgaris | - | - |
KX2-391 Ointment 1% | Phase 3 | Actinic Keratosis | - | - |
Tirbanibulin ointment 1% | Phase 3 | Keratosis, Actinic | - | - |
LAS106521 | Phase 3 | Actinic Keratosis | - | - |
Dapsone Gel | Phase 3 | Acne Vulgaris | - | - |
LAS41008 | Phase 3 | Plaque Psoriasis | - | - |
5-fluorouracil/salicylic acid | Phase 3 | Actinic Keratosis | - | - |
LAS41005 | Phase 3 | Actinic Keratosis | - | - |
Sativex® | Phase 3 | Multiple Sclerosis | - | - |
Dapsone Gel Vehicle | Phase 3 | Acne Vulgaris | - | - |
LAS41004-IMP1 | Phase 2 | Psoriasis | - | - |
50 mg of KX2-391 Ointment 1% | Phase 2 | Actinic Keratosis | - | - |
Experimental: LAS 41004 dosage 1 | Phase 2 | Psoriasis | - | - |
Experimental Tazarotene Gel | Phase 2 | Nail Psoriasis | - | - |
LAD603 | Phase 2 | Alopecia Areata | - | - |
LAS41004 | Phase 2 | Psoriasis | - | - |
LAD191 | Phase 2 | Hidradenitis Suppurativa | - | - |
LAS189961 | Phase 2 | Tinea Pedis | - | - |
50 mg P005672-HCl | Phase 2 | Acne Vulgaris | - | - |
LAS41007 o.d. | Phase 2 | Actinic Keratosis | - | - |
LAS 41004 | Phase 2 | Psoriasis | - | - |
LAS 41002 | Phase 2 | Atopic Eczema | - | - |
LAS189962 | Phase 2 | Candidiasis | - | - |
LAS41003 | Phase 2 | Eczema | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Almirall, S.A.'s drug pipeline?→
CatalystAlert tracks 27 drug candidates in Almirall, S.A.'s (ALM.MC) pipeline across Phase 3, Phase 2. Its lead program is Lebrikizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Almirall, S.A.'s next FDA catalyst?→
Almirall, S.A.'s (ALM.MC) next tracked catalyst is a Phase 3 expected April 25, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALM.MC biotech catalysts?→
Add ALM.MC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Almirall, S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.